Literature DB >> 2857488

Conformationally restricted analogs of somatostatin with high mu-opiate receptor specificity.

J T Pelton, K Gulya, V J Hruby, S P Duckles, H I Yamamura.   

Abstract

A series of cyclic, conformationally restricted analogs of somatostatin have been prepared and tested for their ability to inhibit the binding of [3H]naloxone and [D-Ala2, D-Leu5] [3H]enkephalin to rat brain membranes. The most potent analog, D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 where Pen is penicillamine in [D-Phe5, Cys6, Tyr7, D-Trp8, Pen11]somatostatin-(5-12)-octapeptide amide, exhibited high affinity for mu-opiate receptors (IC50 value of [3H]naloxone = 3.5 nM), being 7800 times more potent than somatostatin. The cyclic octapeptide also displayed high mu-opiate receptor selectivity with an IC50 [( D-Ala2,D-Leu5]enkephalin)/IC50 (naloxone) ratio of 271. The high affinity and selectivity of the somatostatin analog for mu-opiate receptors may be of use in examining the physiological role(s) of the mu-opiate receptor.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2857488      PMCID: PMC397007          DOI: 10.1073/pnas.82.1.236

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  12 in total

1.  [Di-tert.-butyl-dicarbonate, a useful tert.-Butyloxycardonylating reagent (author's transl)].

Authors:  L Moroder; A Hallett; E Wünsch; O Keller; G Wersin
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1976-11

2.  Synthesis of specifically deuterated S-benzylcysteines and of oxytocin and related diastereomers deuterated in the half-cystine positions.

Authors:  D A Upson; V J Hruby
Journal:  J Org Chem       Date:  1976-04-16       Impact factor: 4.354

3.  Somatostatin and ACTH are peptides with partial antagonist-like selectivity for opiate receptors.

Authors:  L Terenius
Journal:  Eur J Pharmacol       Date:  1976-07       Impact factor: 4.432

4.  Highly active cyclic and bicyclic somatostatin analogues of reduced ring size.

Authors:  D F Veber; F W Holly; R F Nutt; S J Bergstrand; S F Brady; R Hirschmann; M S Glitzer; R Saperstein
Journal:  Nature       Date:  1979-08-09       Impact factor: 49.962

5.  Increased coupling yields in solid phase peptide synthesis with a modified carbodiimide coupling procedure.

Authors:  H Hagenmaier; H Frank
Journal:  Hoppe Seylers Z Physiol Chem       Date:  1972-12

6.  Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides.

Authors:  E Kaiser; R L Colescott; C D Bossinger; P I Cook
Journal:  Anal Biochem       Date:  1970-04       Impact factor: 3.365

7.  Somatostatin receptor binding in rat cerebral cortex. Characterization using a nonreducible somatostatin analog.

Authors:  A J Czernik; B Petrack
Journal:  J Biol Chem       Date:  1983-05-10       Impact factor: 5.157

8.  Somatostatin: clinical importance and outlook.

Authors:  K Lundbaek
Journal:  Metabolism       Date:  1978-09       Impact factor: 8.694

9.  Morphiceptin (NH4-tyr-pro-phe-pro-COHN2): a potent and specific agonist for morphine (mu) receptors.

Authors:  K J Chang; A Lillian; E Hazum; P Cuatrecasas; J K Chang
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

10.  The binding of [3H]nitrendipine to receptors for calcium channel antagonists in the heart, cerebral cortex, and ileum of rats.

Authors:  F J Ehlert; W R Roeske; E Itoga; H I Yamamura
Journal:  Life Sci       Date:  1982-06-21       Impact factor: 5.037

View more
  13 in total

1.  Peptide bicycles that inhibit the Grb2 SH2 domain.

Authors:  Justin S Quartararo; Pianpian Wu; Joshua A Kritzer
Journal:  Chembiochem       Date:  2012-06-11       Impact factor: 3.164

Review 2.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

3.  The inhibitory effect of somatostatin peptides on the rat anococcygeus muscle in vitro.

Authors:  T Priestley; G N Woodruff
Journal:  Br J Pharmacol       Date:  1988-05       Impact factor: 8.739

Review 4.  Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations.

Authors:  V J Hruby; F al-Obeidi; W Kazmierski
Journal:  Biochem J       Date:  1990-06-01       Impact factor: 3.857

Review 5.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

6.  Contribution of adrenomedullin to the switch of G protein-coupled μ-opioid receptors from Gi to Gs in the spinal dorsal horn following chronic morphine exposure in rats.

Authors:  Dongmei Wang; Juan Zeng; Qi Li; Jianzhong Huang; Réjean Couture; Yanguo Hong
Journal:  Br J Pharmacol       Date:  2016-02-25       Impact factor: 8.739

Review 7.  Pharmacology of nociceptin and its receptor: a novel therapeutic target.

Authors:  G Calo'; R Guerrini; A Rizzi; S Salvadori; D Regoli
Journal:  Br J Pharmacol       Date:  2000-04       Impact factor: 8.739

8.  Effects of Zusanli electroacupuncture on somatostatin expression in the rat brainstem.

Authors:  Qinghua Tian; Lihua Wang; Lifen Yao; Liming Zhang; Huixue Zhang
Journal:  J Mol Neurosci       Date:  2012-06-29       Impact factor: 3.444

Review 9.  Organic chemistry and biology: chemical biology through the eyes of collaboration.

Authors:  Victor J Hruby
Journal:  J Org Chem       Date:  2009-12-18       Impact factor: 4.354

Review 10.  The beta-D-glucose scaffold as a beta-turn mimetic.

Authors:  Ralph F Hirschmann; K C Nicolaou; Angie R Angeles; Jason S Chen; Amos B Smith
Journal:  Acc Chem Res       Date:  2009-10-20       Impact factor: 22.384

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.